May 15, 2008
Sanofi-Aventis
Sanofi-Aventis confirms forecast for 2008 growth in earnings per share, adjusted outside elements, around 7%.
This forecast is based on a euro / dollar parity constant 1371 dollar for one euro, "said Gerard Le Fur, Director General of World No. 4 of the pharmacy, at the general meeting of shareholders.
He also reiterated that the laboratory could, before the end of 2010, to submit applications for placing on the market of nearly 30 new treatments.
For the single year 2008 it plans to submit the Multaq in atrial arrhythmias, Eplivansérine (maintenance of sleep), Aflibercept (treatment of ovarian cancer), the S-1 (gastric cancer), Sarédutant the (depression) and Amibegron (depression).
STUDY PUBLISHED ON THURSDAY MULTAQ
Regarding Multaq, Gerard Le Fur said that the results of the study Athena on the efficacy of this treatment on morbidity (cardio vascular hospitalisation) and mortality would be published on Thursday.
"We see no reason to be pessimistic about these kinds of results," he said, noting that the cardiac rhythm disorders related 5 to 6 million patients in Europe and the USA.
Questioned on the risk of Germany copy of Plavix, an anticoagulant flagship of the group, he reiterated the determination of Sanofi-Aventis "very vigorously defend" its industrial property on the medicine.
He refused any further comment, citing the lack of information on the case of the Swiss group Schweizerhall.
The latter s'apprêterait to launch a generic Plavix competitor on the German and Luxembourgish.
In addition, Gerard Le Fur has reiterated that Sanofi-Aventis would continue this year "adaptation measures selective."
He said that the group had been able, as he was considering, make an acquisition in Japan, but he had taken in this country the rights of some of its drugs until then entrusted to third parties.
"We'd love to buy a Japanese laboratory if an opportunity presented itself," he added.
Sanofi-Aventis has also announced its shareholders setting up a "strategic committee" chaired by Jean-Francois Dehecq, the chairman of the group, whose mission is to propose "broad guidelines for enterprise development" .
Finally, the General Assembly has voted a new share buyback program after the completion of one of about three billion euros in 2007.
by erectusplus at 10:52 AM |
0 Comments:
Post a Comment
<< Home